Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Reforms fail to keep markets upbeat
Tue, 25 Sep Closing

Despite the restructuring plan for the power sector yesterday, investors in Indian equity markets chose to stay on the sidelines throughout the session today. After hovering close to the dotted line for most of the session, the indices closed marginally higher today. While the Sensex today closed higher by around 21 points, gains on the NSE-Nifty came in at around 4 points. The BSE Mid Cap and BSE Small Cap indices ended higher by around 0.5% each. Select FMCG and consumer durable stocks managed to find investor interest.

Asian indices closed a mixed bag today with Europe too trading in the negative currently. The rupee was placed at Rs 53.42 to the dollar at the time of writing.

Despite the government's latest reforms for the power sector, PSU power stocks National Thermal Power Corporation (NTPC) and Power Grid Corporation failed to find investor interest today. NTPC is the largest power generating major in the country. It has also diversified into hydro power, coal mining, power equipment manufacturing, oil & gas exploration, power trading & distribution. The company has recently raised US$ 500 m via 10-year US dollar denominated bond offering in the US bond market. The coupon for NTPC's bond has been fixed at 4.8%. With coal supplies and bank funding expected to get streamlined, NTPC may well be on its way to set up generation capacities in line with its long term plans.

The country's largest drug-maker, Ranbaxy Laboratories, has missed out on the 'first-day launch' of its generic version of Novartis' best-seller hypertension drug Diovan in the US. This is because the company is yet to get the US Food and Drug Administration's (FDA's) approval for the generic version of the drug, Valsartan. The company was scheduled to launch its drug on September 21, 2012, the day from when Diovan's patent expired. The company has the exclusive rights to market the generic for 180 days, after emerging as the first company to successfully challenge Novartis' patent for Diovan. However, Sandoz, the generic arm of Novartis, unveiled Diovan HCT, its low-cost version with a licence from Novartis. Similarly, Mylan Inc too started selling the same low-cost combination drug recently. The stock of Ranbaxy closed 1% higher today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Reforms fail to keep markets upbeat". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.